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Author's reply
Stephan et al. 1 raise important questions concerning the generalizability of the results we reported in our paper on calibration of commercial prostate-speci¢c antigen (PSA) assays. 2 Their main contention is that our use of arti¢cial samples could invalidate our conclusions since we might be reporting artefactual results due to matrix e¡ects of the specimen substrate. At this point, we should note that we used the WHO reference materials in the recommended manner; it would not be possible for manufacturers to claim calibration of their assays to the WHO standard if they were not equimolar or susceptible to major matrix e¡ects.
We agree that the matrix used can cause slight di¡erences in the results; Ishibashi's editorial 3 to Stephan et al.'s paper on which the data in their current letter is based 4 states that in internal studies conducted by that author, matrix e¡ects were less than 10% except for the Immulite (Diagnostic Products Corporation) platform where matrix e¡ects were estimated at 18%. Our own internal comparisons between results based on clinical samples and similar arti¢cial samples to those used in our paper agree with these estimates; we observe matrix e¡ects that are normally under 10%. Thus the apparent discrepancy in results between our study and that of Stephan et al. is, we believe, due to more 
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We agree that the matrix used can cause slight di¡erences in the results; Ishibashi's editorial 3 to Stephan et al.'s paper on which the data in their current letter is based 4 states that in internal studies conducted by that author, matrix e¡ects were less than 10% except for the Immulite (Diagnostic Products Corporation) platform where matrix e¡ects were estimated at 18%. Our own internal comparisons between results based on clinical samples and similar arti¢cial samples to those used in our paper agree with these estimates; we observe matrix e¡ects that are normally under 10%. Thus the apparent discrepancy in results between our study and that of Stephan et al. is, we believe, due to more than just the e¡ects of the sample matrix and deserves further exploration. Taking account of our internal estimates of the matrix e¡ects does not change the overall results of our manuscript; the characterization that we proposed for assays in terms of acceptable and unacceptable performance remains.
Stephan et al. 1 also comments on the need for assay-speci¢c and clinically validated cut-points. Similarly, Dorizzi et al.'s 5 comments on the lack of interchangeability of PSA assays and the problem of the same manufacturers reagents producing di¡erent results on di¡erent platforms. As we noted in our original manuscript the background to our study is the decision taken in the UK that a set of common age-speci¢c cut-o¡ points will be adopted by the Prostate Cancer Risk Management Programme. It was never the goal to have complete interchangeability of PSA assays; however without harmonization to a common standard, the impact of using a single cut-o¡ is to increase clinical errors. The impact of this lack of harmonization was demonstrated by us in a previous manuscript and it was this study which lead to our proposed range of 710% to minimize clinical errors. 6 If such harmonization is achieved, we believe that assay-speci¢c cut-o¡s will be unnecessary as they will have only minimal e¡ects on clinical errors. However, if laboratories or manufacturers are changing the methods used to assess PSA concentrations, then clinicians should be aware of such changes to ensure appropriate management of men who are being regularly monitored by means of repeat PSA testing. 
